My Cart
You have no items in your shopping cart.
15 items
Creating an account has many benefits:
# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA4418184 | B | Inhibition of NAPRT (unknown origin) | Homo sapiens | 22 | ALA4417637 | single protein format | Patent Bioactivity Data | |
2. | ALA4418185 | B | Inhibition of NAPRT in human OVCAR5 cells assessed as potentiation of NAMPT inhibitor FK866-induced cytotoxicity by measuring reduction in cell viability at 250 uM to 1 mM incubated for 72 hrs by SRB assay | Homo sapiens | 1 | ALA4417637 | cell-based format | Patent Bioactivity Data | |
3. | ALA4418186 | B | Inhibition of NAPRT in human OVCAR5 cells assessed as potentiation of NAMPT inhibitor FK866-induced cytotoxicity by measuring reduction in cell viability at 300 uM to 1 mM incubated for 72 hrs by SRB assay | Homo sapiens | 2 | ALA4417637 | cell-based format | Patent Bioactivity Data | |
4. | ALA4418187 | B | Inhibition of NAPRT in human CCRF-CEM cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry | Homo sapiens | 1 | ALA4417637 | cell-based format | Patent Bioactivity Data | |
5. | ALA4418188 | B | Inhibition of NAPRT in human Jurkat cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry | Homo sapiens | 1 | ALA4417637 | cell-based format | Patent Bioactivity Data | |
6. | ALA4418189 | B | Inhibition of NAPRT in human ML2 cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry | Homo sapiens | 1 | ALA4417637 | cell-based format | Patent Bioactivity Data | |
7. | ALA4418190 | B | Inhibition of NAPRT in human NOMO cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry | Homo sapiens | 1 | ALA4417637 | cell-based format | Patent Bioactivity Data | |
8. | ALA4418191 | B | Inhibition of NAPRT in human NB4 cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry | Homo sapiens | 1 | ALA4417637 | cell-based format | Patent Bioactivity Data | |
9. | ALA4418192 | B | Inhibition of NAPRT in human NAMALWA cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry | Homo sapiens | 1 | ALA4417637 | cell-based format | Patent Bioactivity Data | |
10. | ALA4418193 | B | Inhibition of NAPRT in human Daudi cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry | Homo sapiens | 1 | ALA4417637 | cell-based format | Patent Bioactivity Data | |
11. | ALA4418194 | B | Inhibition of NAPRT in human Raji cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry | Homo sapiens | 1 | ALA4417637 | cell-based format | Patent Bioactivity Data | |
12. | ALA4418195 | B | Inhibition of NAPRT in human ARH77 cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry | Homo sapiens | 1 | ALA4417637 | cell-based format | Patent Bioactivity Data | |
13. | ALA4418196 | B | Inhibition of NAPRT in human RPMI8226 cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry | Homo sapiens | 1 | ALA4417637 | cell-based format | Patent Bioactivity Data | |
14. | ALA4418197 | B | Inhibition of NAPRT in human U266 cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incubated for 48 hrs by Annexin-V/7-AAD staining based flow cytometry | Homo sapiens | 1 | ALA4417637 | cell-based format | Patent Bioactivity Data | |
15. | ALA4418200 | B | Inhibition of NAPRT in human OVCAR5 cells assessed as potentiation of NAMPT inhibitor GMX-1778-induced cytotoxicity by measuring reduction in cell viability at 1 mM incubated for 72 hrs by SRB assay | Homo sapiens | 1 | ALA4417637 | cell-based format | Patent Bioactivity Data |